Novartis

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment includes researching, distributing and selling patented pharmaceuticals. The Sandoz segment focuses on marketing finished dosage form medicines and intermediary products including active pharmaceutical ingredients. The Corporate segment is involved in group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Autodesk

Roku

Splunk

Roku, Autodesk, Splunk and Novartis are our top stock trades on Friday. Going into the long weekend, see why we picked them for next week.

4 Top Stock Trades for Tuesday: ROKU, ADSK, SPLK, NVS

The therapy, Zolgensma, is a one-time treatment for spinal muscular atrophy — a muscle-wasting disease and leading genetic cause of infant mortality, affecting one in every 11,000 live births.

FDA approves Novartis' $2 million gene therapy for spinal muscular atrophy

Novartis stock popped Friday as the Food and Drug Administration approved its gene therapy, dubbed Zolgensma, for spinal muscular atrophy treatment, throwing a challenge to Biogen and Ionis.

Novartis Gains FDA Approval For Gene Therapy Rivaling Biogen, Ionis

Novartis (NVS) reports encouraging data on combination asthma drug. The company also highlights its growth plans at its annual meet.

Novartis Reports Data on Asthma Drug, Update from Annual Meet

Novartis Chief Executive Vas Narasimhan said takeover targets in China for global pharmaceuticals companies are scarce due to little drug discovery by local firms, worries over data quality and regulatory standards in the most-populous country.

Novartis CEO sees China M&A hampered by data, regulatory standards

Novartis could reach its main drugs business's margin target "a little sooner" than 2022, as it now forecasts, as it cuts costs and as new drugs including gene therapy accelerate, Chief Executive Vas Narasimhan told investors.

Novartis CEO sees chance to accelerate profit margin target

Novartis has 25 potential blockbuster treatments in development, the company said ahead of a management event in the United States on Thursday.

Novartis has 25 blockbusters in the pipeline - CEO

"I can't remember a time at Novartis where year after year after year we have these significant medicines getting launched," CEO Vasant Narasimhan says.

Novartis CEO calls for fixing 'distortions' in health care system ahead of slate of drug launches

Tilray Brands

Speaking with CNBC's Jim Cramer from the "Healthy Returns" conference in New York City, Novartis CEO Vas Narasimhan says cannabis is "not a focus" for the pharma company.

Novartis CEO says cannabis not company focus despite Tilray partnership

Altria

Constellation Brands

Forget the volatile marijuana stocks. Their partners could be a better and safer investment for most investors.

3 Ways to Buy Into the Marijuana Boom Without the Risk

The current global health system treats chronic diseases with a pay-as-you-go model, spreading costs over months and years

Commentary: Novartis CEO says gene therapies promise to upend US health system, pricing structure

Novartis on Monday said claims of price fixing against its Sandoz generics unit amid a U.S. probe of 20 drugmakers are without merit, with the Swiss company vowing to fight allegations in a lawsuit filed last week.

Novartis vows to fight U.S. price-fixing claims against Sandoz unit

Takeda Pharmaceutical

Takeda Pharmaceutical Co Ltd agreed to sell its dry eye drug to Swiss drugmaker Novartis AG for $3.4 billion and potential milestone payments of up to $1.9 billion, in the first divestment since its takeover of Britain's Shire.

Takeda sells dry eye drug to Novartis to help cut debt

Novartis AG NVS, +0.99% said late Wednesday it will acquire Takeda Pharmaceutical Co. dry-eye treatment Xiidra.

Novartis buys dry-eye drug Xiidra rights from Takeda for $3.4 billion

Gene therapy is an emerging field of drug development. From large-cap pharma to tiny biotechs, many companies are trying to make a name for themselves in gene therapy — a novel approach to treating or preventing diseases using genes.

What's The Buzz Around Novartis' Gene Therapy Zolgensma?

Novartis (NVS) CEO Vasant Narasimhan on Q1 2019 Results - Earnings Call Transcript

Novartis (NVS) beats on Q1 earnings, sales marginally miss estimates.

Novartis (NVS) Q1 Earnings Beat Estimates, Revenues Up Y/Y

Novartis on Wednesday reported adjusted earnings of $1.21 per share on $11.11 billion in sales for its first quarter ended XX.

Novartis Earnings Beat But Drug Giant's Sales Miss

Bristol-Myers

Exelixis

Merck

Pfizer

Kidney-Cancer Market: Good for Patients, Hard for Investors

Atara Biotherapeutics

CRISPR Therapeutics

Gilead Sciences

Atara Biotherapeutics and Crispr Therapeutics stand out as strong takeover candidates. Here's why.

2 Best Biotech Buyout Plays

REGENXBIO

A second baby reportedly died in a study of Novartis' gene therapy, Zolgensma — sending shares of biotech Regenxbio into free fall Monday.

A Second Baby Died In A Gene Therapy Study — Slugging This Biotech Stock

An early look at the phase 3 STR1VE trial data reinforces data from phase 1 START trial for Zolgensma.

Ionis's Spinraza Still Bests Novartis's Zolgensma

bluebird bio

Celgene

Editas Medicine

Guardant Health Inc

Genomic Health

Illumina

Myriad Genetics

Invitae

Spark Therapeutics

Pacific Biosciences of California

Roche Holding AG

Thermo Fisher Scientific

These next-generation companies are working on game-changing ways to obtain and profit from genetic insight.

Top Gene-Sequencing Stocks for 2019

General Mills

Verizon

Verizon Communications Inc 5.9 % Notes 2014-15.2.54 Sr

Sometimes you have to act while the iron's hot, and that's the case with these three big-name dividend payers right now.

Top Dividend Stocks to Buy Right Now

Novartis announced that the FDA had accepted its BLA for brolucizumab to treat patients with wet age-related macular degeneration.

Novartis' BLA Acceptance Allows Entrance Into Large And Turbulent Wet AMD Market

News for Novartis Stock (NVS)